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Abstract
Endotoxemia, whether primary (due to Gram-negative infection) or
secondary (due to epithelial barrier dysfunction), appears to be
extremely common in the critically ill and injured. High levels of
endotoxin activity are associated with worse clinical outcomes. In
Japan, polymyxin B hemoperfusion has been available to treat
endotoxemia for more than ten years. Multiple small trials, often
limited by methodological quality, show that polymyxin B hemo-
perfusion may have favorable effects on survival and hemo-
dynamics. Further study of this therapy would seem justified.
Cruz and colleagues [1] report a meta-analysis examining a
novel treatment of sepsis and septic shock predicated on the
removal of endotoxin from the bloodstream. The term endo-
toxin came from the 19th century discovery that portions of
various Gram-negative bacteria could cause toxicity. Over the
next 50 years, studies revealed that the effects of endotoxin
were due to lipopolysaccharide found in the bacteria’s outer
membrane. Endotoxin need not be derived from pathogenic
strains of bacteria; indeed, commensal microbial flora of the
gut is an excellent source [2]. However, endotoxin is
recognized as a key trigger of sepsis and septic shock [3].
Although our gut contains large quantities of endotoxin,
endotoxin is scarcely detectable in the blood of healthy
humans [4]. However, in sepsis, endotoxin levels in the blood
can increase as much as 1,000-fold, even when there is no
Gram-negative infection identified [5], perhaps occurring
secondary to increased permeability of the gastrointestinal
tract and subsequent translocation of bacteria or bacterial
products (that is, endotoxin) [6]. Whatever the source, endo-
toxemia is associated with increased organ dysfunction and
risk of death in critically ill patients [7]. Furthermore, blood
levels of endotoxin have been reported to vary over time [8] in
patients, suggesting subsequent waves of exposure either
from infection or from intestinal translocation.
In the past, endotoxin was measured in the blood using a
limulus assay where an aqueous extract of blood cells
(amebocytes) from the horseshoe crab (Limulus polyphemus)
is combined with a pyrochrome yielding a chromogenic
readout. However, this assay detects only circulating endo-
toxin and most endotoxin is rapidly taken up by cells.
Recently, the US Food and Drug Administration approved a
method of assay for endotoxin activity in whole blood using a
chemiluminescent detection system (Spectral Diagnostics,
Toronto, Canada). The assay involves incubating whole blood
with an anti-lipopolysaccharide antibody and then stimulating
it with opsonized zymosan. The resulting respiratory burst
activity of the subjects own white blood cells is then detected
as light release from a lumiphor, which is used to quantify the
amount of endotoxin activity [9]. Studies using this assay
have shown that increased endotoxin activity is common in
critically ill patients [7].
However, despite new methods of detecting endotoxin,
treatment is quite limited. Bacterial infection is treated with
antibiotics but there is no effective method of restoring gut
barrier function. Furthermore, many antibiotics result in
endotoxin release as bacterial are killed [10]. Anti-endotoxin
therapies have been disappointing. Although an earlier trial
suggested benefit from an anti-endotoxin antibody (HA-1A)
when post hoc analysis was limited to subjects with Gram-
negative infection [11], a subsequent trial failed to show a
benefit in this population [12]. A second drug (E5) also failed
to demonstrate benefit in patients with confirmed Gram-
negative sepsis [13]. However, the activity of these antibody
therapies in endotoxemia has been questioned.
Polymyxin B is an antibiotic that has high affinity for endo-
toxin, although it is associated with neurotoxicity and nephro-
toxicity, precluding its systemic use. However, polymyxin B
has been bound and immobilized to polystyrene fibers and
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when used for hemoperfusion can effectively bind endotoxin
both in vitro and in vivo [14]. This therapy has been available
in Japan for more than a decade and thousands of patients
have been treated. Unfortunately, despite widespread use in
Japan, no large randomized trials have established efficacy of
polymyxin B hemoperfusion. Several small studies have been
conducted, however, and most have studied similar patients.
Cruz and colleagues [1] identified a total of 28 publications,
including 9 randomized controlled trials, of polymyxin B
hemoperfusion for treatment of sepsis and septic shock [1].
Their results reveal significant heterogeneity among trials
(p < 0.001). However, these differences became non-
significant when the analysis was adjusted for baseline blood
pressure. Polymyxin B hemoperfusion was associated with a
significantly lower mortality compared to conventional therapy
(relative risk 0.53, 95% confidence interval 0.43 to 0.65).
Secondary endpoints such as mean arterial pressure
increase, vasopressor decrease, and mean partial pressure of
oxygen in arterial blood/forced inspiratory pressure of oxygen
ratio increase were also highly significant. However, the trials
assessed were limited by methodological quality. Neverthe-
less, polymyxin B hemoperfusion appears to have favorable
effects on survival and hemodynamics and the authors argue
for the need for further rigorous study of this therapy.
Indeed, given the poor overall outcomes associated with
endotoxemia, polymyxin B hemoperfusion would seem to be a
welcome intervention, particularly now that better methods for
detection of endotoxemia have become available. Thus, the
time is right for an adequately powered trial of this promising
therapy.
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